General information:
Substance group: Antipsychotic, atypical fresh-lipople optic ATC: N05AX12
Trade names: Aripiprazol-*®, Abilify®, Aripipan®, Arpoya®
available doses: tablets 5 / 10 / 15 / 20 / 30 mg, melting tablets 10 / 15 mg, solution to
Take 1 mg/mL, solution for injection 7.5 mg/mL, powder+ solvents for depot
Injection 300 / 400 mg
Reference ranges:
150-500 µg/L
Toxic plasma mirrors: from 1.000 µg/L
Pharmacokinetics:
T1⁄2 : 75 h (- 146 h ultra-slow-metabolizer)
Tmax : 3 – 5 h
Bioavailability: 87%
Protein binding: > 99%
Clearance: 0.7 mL/min
Excretion: Faeces: 60%; urine: 27%
Metabolism: hepatic
Time to steady state: 2 weeks
Sampling:
Material: Serum (Monovette brown) Minimum volume for analysis: 500µl
Recommendation: trough level (directly before the next intake)
Requirement (internal): about Orbis requirement (external):
Analytics:
Test principle: liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS)
Protein precipitation with acetonitrile, chromatographic separation, mass spectrometry
Analysis according to mass charge ratio
Analysis system: triple stage Quadrupol mass spectrometer (LC-MS/MS)
Findings communication: on the same working day, via LIMS
DrugBank: https://go.drugbank.com/drugs/DB01238